S1801: A randomized phase II trial of adjuvant versus neoadjuvant pembrolizumab (PEM) for melanoma.

被引：0

作者：

Patel, Sapna Pradyuman

Othus, Megan

Moon, James

Tetzlaff, Michael T.

Buchbinder, Elizabeth Iannotti

Sondak, Vernon K.

Lowe, Michael C.

Campos, Danae

Sharon, Elad

Korde, Larissa A.

Carson, William Edgar

Ribas, Antoni

Grossmann, Kenneth F.

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[3] Southwest Oncol Grp, Stat Ctr, Seattle, WA USA

[4] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[6] Emory Univ, Dept Surg, Atlanta, GA USA

[7] SWOG Operatons Off, San Antonio, TX USA

[8] NCI, Bethesda, MD 20892 USA

[9] NCI, Clin Invest Branch, Bethesda, MD 20892 USA

[10] Ohio State Univ, Dept Surg, Comprehens Canc Ctr, Columbus, OH 43210 USA

[11] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA

[12] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

来源：

基金：

美国国家卫生研究院;

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS10090

引用

页数：2